MODALIS THERAPEUTICS CORPORATION Financials Modalis Therapeutics Corporation
Equities
4883
JP3922600006
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 77 JPY | 0.00% |
|
-1.28% | -37.90% |
| Apr. 15 | Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs | MT |
| Feb. 23 | Modalis Therapeutics to Reduce Stated Capital and Capital Reserves | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 63,031 | 17,753 | 9,769 | 3,916 |
| Enterprise Value (EV) 1 | 57,610 | 12,817 | 6,836 | 2,445 |
| P/E ratio | -130 x | -23.9 x | -3.61 x | -1.61 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 184 x | 17,753 x | 244 x | - |
| EV / Revenue | 168 x | 12,817 x | 171 x | - |
| EV / EBITDA | -168,944,106 x | -11,030,009 x | -3,523,926 x | -1,031,796 x |
| EV / FCF | -54,106,541 x | -16,285,731 x | -4,876,623 x | -1,724,435 x |
| FCF Yield | -0% | -0% | -0% | -0% |
| Price to Book | 10.2 x | 3.2 x | 3.35 x | 3 x |
| Nbr of stocks (in thousands) | 28,495 | 28,961 | 29,162 | 31,577 |
| Reference price 2 | 2,212 | 613.0 | 335.0 | 124.0 |
| Announcement Date | 3/31/21 | 3/29/22 | 3/28/23 | 3/27/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 65 | 644 | 342 | 1 | 40 | - |
| EBITDA | - | - | -341 | -1,162 | -1,940 | -2,369 |
| EBIT 1 | -214 | 157 | -398 | -1,239 | -2,063 | -2,370 |
| Operating Margin | -329.23% | 24.38% | -116.37% | -123,900% | -5,157.5% | - |
| Earnings before Tax (EBT) 1 | -213 | 145 | -440 | -744 | -2,706 | -2,390 |
| Net income 1 | -217 | 140 | -448 | -738 | -2,702 | -2,391 |
| Net margin | -333.85% | 21.74% | -130.99% | -73,800% | -6,755% | - |
| EPS 2 | -1.722 | 5.939 | -17.00 | -25.67 | -92.83 | -77.21 |
| Free Cash Flow | - | - | -1,065 | -787 | -1,402 | -1,418 |
| FCF margin | - | - | -311.33% | -78,700% | -3,504.69% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 6/26/20 | 6/26/20 | 3/31/21 | 3/29/22 | 3/28/23 | 3/27/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | - | 1.1 | - | - | 40 | - | 40 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -477.3 | -200 | - | -466 | -402 | -868 | -570 | -625 | -514 | -530 | -1,044 | -565 |
| Operating Margin | - | -43,392.55% | - | - | -1,165% | - | -2,170% | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | 20.9 | -196 | -569.9 | -443 | - | -780 | -534 | - | -532 | - | -1,032 | -548 |
| Net income 1 | - | 17.7 | -198 | -557.6 | -438 | - | -775 | -534 | - | -532 | - | -1,033 | -548 |
| Net margin | - | 1,609.27% | - | - | -1,095% | - | -1,937.5% | - | - | - | - | - | - |
| EPS 2 | - | 0.6200 | -6.940 | -19.38 | -15.13 | -11.57 | -26.70 | -18.34 | -47.81 | -17.86 | -16.84 | -34.70 | -17.59 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/14/20 | 8/5/21 | 11/5/21 | 2/14/22 | 5/9/22 | 8/5/22 | 8/5/22 | 11/7/22 | 2/13/23 | 5/9/23 | 8/7/23 | 8/7/23 | 11/7/23 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1,205 | 3,857 | 5,421 | 4,936 | 2,933 | 1,471 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | -1,065 | -787 | -1,402 | -1,418 |
| ROE (net income / shareholders' equity) | - | 5.55% | -8.92% | -12.6% | -63.7% | -111% |
| ROA (Net income/ Total Assets) | - | 3.8% | -4.87% | -12.5% | -28% | -57.5% |
| Assets 1 | - | 3,682 | 9,199 | 5,883 | 9,638 | 4,160 |
| Book Value Per Share 2 | 9.540 | 153.0 | 218.0 | 192.0 | 100.0 | 41.30 |
| Cash Flow per Share 2 | 9.560 | 154.0 | 190.0 | 170.0 | 99.90 | 56.50 |
| Capex | - | - | 16 | 107 | 197 | 39 |
| Capex / Sales | - | - | 4.68% | 10,700% | 492.5% | - |
| Announcement Date | 6/26/20 | 6/26/20 | 3/31/21 | 3/29/22 | 3/28/23 | 3/27/24 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -37.90% | 16.73M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.67% | 22.15B | |
| -17.37% | 21.02B | |
| -8.96% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 4883 Stock
- Financials Modalis Therapeutics Corporation
